Alias
科研级 Tremelimumab ( 曲美木单抗 ), Anti-CD152 Recombinant Antibody, Research Grade Tremelimumab
Molecular Name
Tremelimumab
Applications
IF, IP, Neut, FuncS, ELISA
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
CTLA4/CD152[Homo sapiens]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Tremelimumab (formerly ticilimumab, CP-675, 206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any.
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。